ERBB3 V855A

CI-VAR-00004655Explore in graph →ENST000000267101.3:c.2564T>CCIViC 781

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
ERBB3 V855A	Afatinib + PertuzumabSubstitutes	Predictive	D	Supports Sensitivity Response	2	accepted	EID1845 Case report on a novel V855A mutation located in exon 21 of the HER3 tyrosine kinase domain and found in the tumor specimen of an adolescent patient with a chemotherapy-resistant advanced NSCLC. Prote… (full text at CIViC) PMID 26689995 · Umelo et al., 2016 · Open in CIViC	civic
Unmapped disease1unmapped disease
ERBB3 V855A	(functional)	Functional	D	Supports Gain Of Function	3	submitted	EID10060 BaF3 cells were trasnfected with WT HER2, WT HER3, or mutant HER3 (V855A). The HER3 mutant enhanced phosphorylation only in the presence of HER2 WT.

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.